NOT FOR DISTRIBUTION
Header cover image

Market Cap

€7.0b

Last Updated

2021/04/14 19:46 UTC

Data Sources

Company Financials +

Executive Summary

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. More Details


Snowflake Analysis

6 star dividend payer with solid track record.


Similar Companies

Share Price & News

How has Sinopharm Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: X2S1 is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: Insufficient data to determine X2S1's volatility change over the past year.


Market Performance


7 Day Return

4.5%

X2S1

0.9%

DE Healthcare

0.2%

DE Market


1 Year Return

n/a

X2S1

0.6%

DE Healthcare

42.4%

DE Market

Return vs Industry: Insufficient data to determine how X2S1 performed against the German Healthcare industry.

Return vs Market: Insufficient data to determine how X2S1 performed against the German Market.


Shareholder returns

X2S1IndustryMarket
7 Day4.5%0.9%0.2%
30 Day16.0%5.2%5.1%
90 Day11.5%-2.9%9.6%
1 Yearn/a2.6%0.6%47.0%42.4%
3 Yearn/a-27.9%-31.4%23.5%12.8%
5 Yearn/a-28.5%-33.1%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?

7.88x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: X2S1 (€10.68) is trading above our estimate of fair value (€5.95)

Significantly Below Fair Value: X2S1 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: X2S1 is good value based on its PE Ratio (7.9x) compared to the DE Healthcare industry average (32.5x).

PE vs Market: X2S1 is good value based on its PE Ratio (7.9x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: X2S1 is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: X2S1 is good value based on its PB Ratio (0.9x) compared to the DE Healthcare industry average (1.7x).


Future Growth

How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

7.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: X2S1's forecast earnings growth (7.9% per year) is above the savings rate (0.07%).

Earnings vs Market: X2S1's earnings (7.9% per year) are forecast to grow slower than the German market (20.9% per year).

High Growth Earnings: X2S1's earnings are forecast to grow, but not significantly.

Revenue vs Market: X2S1's revenue (9% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: X2S1's revenue (9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: X2S1's Return on Equity is forecast to be low in 3 years time (12.8%).


Past Performance

How has Sinopharm Group performed over the past 5 years?

10.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: X2S1 has high quality earnings.

Growing Profit Margin: X2S1's current net profit margins (1.6%) are higher than last year (1.5%).


Past Earnings Growth Analysis

Earnings Trend: X2S1's earnings have grown by 10.6% per year over the past 5 years.

Accelerating Growth: X2S1's earnings growth over the past year (14.9%) exceeds its 5-year average (10.6% per year).

Earnings vs Industry: X2S1 earnings growth over the past year (14.9%) exceeded the Healthcare industry 2%.


Return on Equity

High ROE: X2S1's Return on Equity (13.4%) is considered low.


Financial Health

How is Sinopharm Group's financial position?


Financial Position Analysis

Short Term Liabilities: X2S1's short term assets (CN¥267.6B) exceed its short term liabilities (CN¥204.0B).

Long Term Liabilities: X2S1's short term assets (CN¥267.6B) exceed its long term liabilities (CN¥17.3B).


Debt to Equity History and Analysis

Debt Level: X2S1's debt to equity ratio (71%) is considered high.

Reducing Debt: X2S1's debt to equity ratio has increased from 70.9% to 71% over the past 5 years.

Debt Coverage: X2S1's debt is not well covered by operating cash flow (17.5%).

Interest Coverage: X2S1's interest payments on its debt are well covered by EBIT (5.5x coverage).


Balance Sheet


Dividend

What is Sinopharm Group current dividend yield, its reliability and sustainability?

3.44%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: X2S1's dividend (3.43%) is higher than the bottom 25% of dividend payers in the German market (1.06%).

High Dividend: X2S1's dividend (3.43%) is in the top 25% of dividend payers in the German market (3.21%)


Stability and Growth of Payments

Stable Dividend: X2S1's dividends per share have been stable in the past 10 years.

Growing Dividend: X2S1's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (27.1%), X2S1's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: X2S1's dividends in 3 years are forecast to be well covered by earnings (25.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Yong Liu (51 yo)

3.42yrs

Tenure

CN¥7,447,000

Compensation

Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...


CEO Compensation Analysis

Compensation vs Market: Yong's total compensation ($USD1.14M) is below average for companies of similar size in the German market ($USD3.26M).

Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: X2S1's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: X2S1's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sinopharm Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sinopharm Group Co., Ltd.
  • Ticker: X2S1
  • Exchange: DB
  • Founded: 2003
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$64.670b
  • Listing Market Cap: HK$6.954b
  • Shares outstanding: 3.12b
  • Website: https://www.sinopharmgroup.com.cn

Number of Employees


Location

  • Sinopharm Group Co., Ltd.
  • Sinopharm Plaza
  • No. 1001 Zhongshan Road (West)
  • Shanghai
  • Shanghai Province
  • 200051
  • China

Listings


Biography

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution se...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 19:46
End of Day Share Price2021/04/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.